Oppenheimer & CO Inc Clovis Oncology, Inc. Transaction History

Oppenheimer & CO Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$4.13 - $6.41 $44,261 - $68,695	-10,717 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$4.82 - $7.72 $17,270 - $27,660	-3,583 Reduced 25.06%	10,717 $62,000
Q2 2020 Aug 11, 2020	SELL	$5.69 - $9.69 $54,254 - $92,394	-9,535 Reduced 40.0%	14,300 $97,000
Q1 2020 May 08, 2020	SELL	$3.77 - $11.0 $75 - $220	-20 Reduced 0.08%	23,835 $152,000
Q4 2019 Feb 07, 2020	SELL	$3.0 - $16.43 $2,055 - $11,254	-685 Reduced 2.79%	23,855 $249,000
Q3 2019 Oct 31, 2019	SELL	$3.93 - $15.35 $21,280 - $83,120	-5,415 Reduced 18.08%	24,540 $96,000
Q2 2019 Aug 09, 2019	BUY	$12.81 - $25.67 $22,827 - $45,743	1,782 Added 6.33%	29,955 $445,000
Q1 2019 Apr 24, 2019	BUY	$17.66 - $30.28 $203,460 - $348,855	11,521 Added 69.19%	28,173 $699,000
Q4 2018 Jan 29, 2019	BUY	$11.63 - $32.67 $193,662 - $544,020	16,652 New	16,652 $299,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.